Kimberly Clark Stock Symbol: A Closer Look at NYSE: KMB

The Kimberly Clark stock symbol is NYSE: KMB, a label that's easy to spot on stock market screens and financial reports. This symbol is a shorthand way to identify the company's stock.

Kimberly Clark is a well-established company with a long history dating back to 1872, making it one of the oldest companies listed on the New York Stock Exchange. The company has been around for over 149 years.

The NYSE: KMB stock symbol is used to represent the company's common stock, which is traded on the New York Stock Exchange. This allows investors to buy and sell shares of the company's stock.

Kimberly-Clark's stock performance has been impressive, with a 1-year return of +20.11% and a 5-year return of +17.89%. This is a testament to the company's strong financials and ability to adapt to changing market conditions.

The company's annualized 5-year return of +3.34% is a significant achievement, indicating steady growth over the long term. In comparison, the S&P has an annualized 5-year return of +13.93%, which is a notable difference.

Kimberly-Clark's stock has been a standout performer since its IPO, with a return of +61,056%. This is a staggering figure that highlights the company's remarkable growth and success.

Here's a comparison of Kimberly-Clark's performance to the S&P:

Kimberly-Clark's forecasted annual profit growth is ahead of Wall Street estimates, which is a positive sign for the company's future performance.

Kimberly-Clark's financial health is a key factor in determining its stock's value. The company has consistently generated significant revenue, with a high of $18.5 billion in 2020.

Kimberly-Clark's revenue has been steadily increasing over the years, with a compound annual growth rate (CAGR) of 3.5% from 2016 to 2020.

The company's net income has also been steadily increasing, reaching a high of $2.4 billion in 2020. This growth is a result of the company's focus on innovation and cost reduction.

Kimberly-Clark's gross margin has been around 35% over the past few years, indicating a strong pricing power in the market.

Kimberly-Clark's growth performance continues to be a major concern, with Q4 sales falling 0.8% year-over-year.

The company's Q4 sales decline is a significant issue, as it's a key indicator of the company's overall performance.

Kimberly-Clark's organic sales growth was 2.3%, but this growth was not enough to offset the decline in sales.

This weak growth performance has likely been priced into the stock, keeping its valuation rangebound.

Kimberly-Clark's sales fell 0.8% year-over-year in Q4.

The company's organic sales growth was 2.3%, but that's not enough to boost investor confidence.

Kimberly-Clark's valuation is rangebound, meaning it's stuck in a narrow price range.

The market has likely priced in the downside, reducing the risk of further losses.

Kimberly-Clark's stable business model and consistent dividend growth have made it a favorite among income-focused investors.

However, the company's lack of growth limits its upside potential.

The company's growth has been underperforming, making it a concern for investors.

Kimberly-Clark's Q4 sales fell 0.8% year-over-year, a sign of weak growth performance.

Kimberly-Clark Forecasts Strong Profit Growth. The company is forecasting strong annual profit growth ahead of Wall Street estimates.

This is a significant development, especially considering the current economic climate. Kimberly-Clark is expecting a better-than-expected quarterly sales performance.

The company's Kleenex tissue business is benefitting from a recovery in consumer spending. This is a positive sign for the industry as a whole.

Kimberly-Clark's forecast is a vote of confidence in the company's ability to adapt to changing market conditions.

Kimberly-Clark delivered solid results in its first year of transformation in 2024.

The company established a strong foundation for its Powering Care strategy, which is expected to drive growth and improve its performance.

Kimberly-Clark de Mexico shows stronger growth prospects than its U.S. parent, with nearly doubling its revenues over the past decade.

In 2025, the company is expected to continue its organic growth and operating momentum, as its transformation progresses.

Kimberly-Clark de Mexico's stock remains undervalued, with a 6.5% dividend yield, despite record profits.

Kimberly-Clark operates in over 175 countries worldwide, making it a truly global company.

Their international presence is a key factor in their success, allowing them to reach a vast and diverse customer base.

Kimberly-Clark's global footprint is supported by a network of manufacturing facilities, distribution centers, and sales offices.

The company's international operations are guided by a clear strategy to expand its presence in emerging markets.

Kimberly-Clark's global brands, such as Huggies and Kleenex, are widely recognized and trusted around the world.

Their commitment to quality, innovation, and customer satisfaction has helped the company establish a strong reputation globally.

Kimberly-Clark Corporation's stable business model has made it a long-time favorite for income-focused investors.

The company's growth has been limited, despite its stable business model. This is due in part to recent underperformance.

Kimberly-Clark's consistent dividend growth is a major draw for investors seeking steady income. However, this growth is not enough to offset the company's lack of growth.

The company's fine valuation is a result of its stable business model and consistent dividend growth. This has made it an attractive option for investors seeking income.

Kimberly-Clark's Kleenex tissue business has benefited from a recovery in the market, leading to better-than-expected quarterly sales. However, this growth is not expected to continue at the same pace.

Kimberly-Clark forecast annual adjusted profit growth ahead of Wall Street estimates. This suggests that the company is still capable of delivering strong financial results.